The CELEBRATE trial evaluated efficacy and safety of a novel subcutaneous glycoprotein IIb/IIIa inhibitor administered upon first medical contact for patients with suspected STEMI.
Read Healio's in-depth coverage of the CELEBRATE trial.
CELEBRATE included 2,467 patients with presumed symptoms of STEMI for less than 4 hours who were randomly assigned to a single subcutaneous injection of zalunfiban (RUC-4, CeleCor Therapeutics) or placebo at first medical contact -- home, ambulance or in hospital.
Risk for the primary efficacy endpoint, which was a hierarchical proportional odds model of seven endpoints, including all-cause death, stroke, recurrent MI, acute stent thrombosis, new-onset heart failure or HF rehospitalization, larger infarct size or no endpoint through 30 days, was lower among patients who received the zalunfiban injection compared with placebo. The rate of adverse event-free survival was also higher in the zalunfiban group.
Risk for the primary safety endpoint, which included severe or life-threatening bleeding, was lower in the zalunfiban group.
Angiography results showed faster coronary blood flow among patients assigned zalunfiban.
The CELEBRATE results were presented at the American Heart Association Scientific Sessions and simultaneously published in NEJM Evidence.